Skip to content
Humanigen, Inc. episode artwork

Apr 29, 2020 11 min

Humanigen, Inc.

from OTCQB Podcast Hosted by OTC Markets Group

Humanigen, Inc. (OTCQB: HGEN) is a biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization, and gene-knockout platforms. We welcome back Chairman & CEO of Humanigen, Cameron Durrant, MD, MBA, to explain the significance of "GM-CSF" pathway science for COVID-19 patients.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Humanigen, Inc.

0:00 11:02

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OTCQB Podcast?

This episode is 11 minutes long.

When was this OTCQB Podcast episode published?

This episode was published on April 29, 2020.

Can I download this OTCQB Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.